Company intelligence / Profile preview

Theraly Fibrosis

Baltimore, Maryland, United Statestheralyfibrosis.com ↗

Ownership: Private
Development stage: Other

Overview

Theraly Fibrosis develops therapies targeting fibrotic diseases. Its lead candidate, TLY012—a proprietary recombinant human TRAIL protein—targets DR5 on myofibroblasts to shut down fibrotic pathways. Preclinical studies show reversal of established fibrosis in pancreas, skin, and liver models. The company has received US Orphan Drug Designation for systemic sclerosis and a $3.9M NIH SBIR Phase II grant for chronic pancreatitis development. Clinical trial initiation was anticipated but no published results from completed trials are available.

Therapeutic areas: GastroenterologyRheumatologyOther
Modalities: Recombinant proteins
Industry: Biotech

Drug pipeline

1 asset

TLY012

Preclinical

Partnerships

Exclusive license with Scarab Genomics LLC for bacterial production technologies used in therapeutic protein manufacturing

Beyond the preview

Go deeper on Theraly Fibrosis.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Theraly Fibrosis.